This cohort study uses international registry data to characterize clinical risk factors, microbiology, and outcomes of patients who developed infective endocarditis following transcatheter aortic valve replacement.
This randomized clinical trial compares the effects of use vs nonuse of a cerebral embolic protection device during transcatheter aortic valve implantation (TAVI) on MRI-detected brain lesions in patients with severe aortic stenosis undergoing TAVI.
In this follow-up study of a US registry of patients undergoing transcatheter aortic valve replacement, 1-year outcomes included overall mortality of 23.7%, stroke rate of 4.1%, and a composite of death and stroke of 26.0%.
Dvir and coauthors evaluated data from a multinational valve-in-valve implantation registry to determine survival among patients after transcatheter valve-in-valve implantation inside failed surgical bioprosthetic valves.
In a randomized clinical trial involving 241 patients undergoing transcatheter aortic valve replacement, Abdal-Wahab and co-authors found that use of balloon-expandable valves resulted in a greater rate of device success than use of self-expandable valves.
To report the initial US experience with newly approved transcatheter aortic valve replacement, Mack and coauthors gathered outcome data, including all-cause in-hospital mortality and stroke, from 7710 cases in 224 participating US registry hospitals. Bonow comments in an editorial.
In an analysis of data from 369 226 Medicare beneficiaries who underwent aortic valve replacement between 1999 and 2011, Barreto-Filho and coauthors examined trends in procedure rates, the association with coronary artery bypass graft surgery, and patient outcomes.
This retrospective cohort analysis quantifies survival and major morbidity in patients aged 50 to 69 years receiving bioprosthetic vs mechanical aortic valve replacement.